Irinotecan - Moligand™, ≥99% , Inhibitor of DNA topoisomerase I, CAS No.97682-44-5, Inhibitor of DNA topoisomerase I

CAS: 97682-44-5 Cat. No.: I127961 Peso molecular: 586.68 Número EC: 691-567-9
Disponible para pedir
GRADE & PURITY Moligand™ ? Moligand™ — Aladdin's line of ligands and bioactive small molecules. Use for receptor, pathway, and binding studies needing defined small-molecule tools. ≥99%
Synonyms
MFCD00866307 | AB00698464-10 | D08086 | (+)-7-ethyl-10-hydroxycamptothecine 10-(1,4'-bipiperidine)-1'-carboxylate | (+)-Irinotecan | CPT-11
Storage
Store at 2-8°C,Protected from light
Shipped In
Wet ice
 ·  off list, applied to all prices below.
Size
Estado
Price
Qty
100mg
I127961-100mg
3

55,90US$

83,90US$
Guardar 28,00 US$ (33.37%)
500mg
I127961-500mg
3

209,90US$

219,90US$
Guardar 10,00 US$ (4.55%)
1g
I127961-1g
1

226,90US$

340,90US$
Guardar 114,00 US$ (33.44%)
Enter a quantity for the sizes you want to add.
🧪

Why this grade

Moligand™, ≥99% Moligand™ for sensitive chromatographic and analytical workflows requiring minimal baseline interference.

🌡

Storage & shipping

Store at 2-8°C,Protected from light Ships Wet ice Check lot-specific COA for exact specifications.

📋

Quality documents

SDS, COA, datasheet, and spec sheet available for download. Lot-specific COA accessible via lot number lookup.

📚

Literature proof

Cited in 24 peer-reviewed publications across chromatography, organic synthesis, and cross-coupling reactions.

Descripción general

Irinotecan is a topoisomerase I inhibitor for LoVo cells and HT-29 cells with IC50 of 15.8 μM and 5.17 μM, respectively.

Irinotecan hydrochloride has been used:

in combination with 5-fluorouracil for screening growth inhibitory functionality in MDA-MB-231 breast cancer cells.

in chemosensitivity screening of high-grade appendiceal (HGA) and low-grade appendiceal (LGA) organoids.

as a chemotherapeutic agent in the cytotoxicity studies in combination with heat shock proteins inhibitors (HPSC1) in HT29 colon cancer cells.

Specifications

Sinónimos
MFCD00866307 | AB00698464-10 | D08086 | (+)-7-ethyl-10-hydroxycamptothecine 10-(1, 4'-bipiperidine)-1'-carboxylate | (+)-Irinotecan | CPT-11
Especificaciones y pureza
Moligand™, ≥99%
Mecanismos bioquímicos y fisiológicos
(+)-Irinotecan is an isomer of the Topo I inhibitor Irinotecan
Condiciones de almacenamiento de almacenamiento
Store at 2-8°C, Protected from light
Enviado en
Wet ice
Este producto requiere envío en cadena de frío. Los servicios terrestres y otros servicios económicos no están disponibles.
Grado
Moligand™
Tipo de acción
INHIBITOR
Mecanismo de acción
Inhibitor of DNA topoisomerase I
Pureza
≥99%
Nombres e identificadores
Pubchem Sid504753721
Pubchem Sid Urlhttps://pubchem.ncbi.nlm.nih.gov/substance/504753721
Sonrisas canónicasCCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7
IUPAC Name[(19S)-10,19-diethyl-19-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-7-yl] 4-piperidin-1-ylpiperidine-1-carboxylate
InChIKeyUWKQSNNFCGGAFS-XIFFEERXSA-N
INCHI1S/C33H38N4O6/c1-3-22-23-16-21(43-32(40)36-14-10-20(11-15-36)35-12-6-5-7-13-35)8-9-27(23)34-29-24(22)18-37-28(29)17-26-25(30(37)38)19-42-31(39)33(26,41)4-2/h8-9,16-17,20,41H,3-7,10-15,18-19H2,1-2H3/t33-/m0/s1
Isómeros SMILES CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)[C@@]4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7
Peso molecular 586.68
Reaxy-Rn 4285693
Reaxys-RN_link_address https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=4285693&ln=

Documentation

📋 Safety Data Sheet (SDS)

Comprehensive hazard, handling, storage, and regulatory compliance document.

Download SDS →

✅ Certificate of Analysis (COA)

Lot-specific quality data. Enter your lot number to retrieve the exact COA.

Look up COA →

📊 Datasheet

Quick-reference summary of product specifications and applications.

View datasheet →

🔬 Specification Sheet

Full quality attributes and acceptance criteria for this grade.

View spec sheet →

Advanced Data

Taxonomic Classification

Taxonomy Tree

KingdomOrganic compounds
SuperclassAlkaloids and derivatives
ClaseCamptothecins
SubclassNot available
Intermediate Tree Nodes Not available
Direct ParentCamptothecins
Alternative Parents Quinolines and derivatives  Pyranopyridines  Piperidinecarboxylic acids  Aminopiperidines  Pyridinones  Benzenoids  Tertiary alcohols  Carbamate esters  Heteroaromatic compounds  Trialkylamines  Carboxylic acid esters  Lactams  Lactones  Organic carbonic acids and derivatives  Azacyclic compounds  Oxacyclic compounds  Monocarboxylic acids and derivatives  Organic oxides  Hydrocarbon derivatives  Organopnictogen compounds  Carbonyl compounds  
Molecular FrameworkAromatic heteropolycyclic compounds
Substituents Camptothecin - Pyranopyridine - Quinoline - Piperidinecarboxylic acid - 4-aminopiperidine - Pyridinone - Piperidine - Pyridine - Benzenoid - Carbamic acid ester - Tertiary alcohol - Heteroaromatic compound - Amino acid or derivatives - Tertiary aliphatic amine - Tertiary amine - Carboxylic acid ester - Lactam - Lactone - Carbonic acid derivative - Oxacycle - Azacycle - Organoheterocyclic compound - Carboxylic acid derivative - Monocarboxylic acid or derivatives - Hydrocarbon derivative - Organonitrogen compound - Organooxygen compound - Organopnictogen compound - Alcohol - Carbonyl group - Organic oxygen compound - Organic nitrogen compound - Organic oxide - Amine - Aromatic heteropolycyclic compound
DescripciónThis compound belongs to the class of organic compounds known as camptothecins. These are heterocyclic compounds comprising a planar pentacyclic ring structure, that includes a pyrrolo[3,4-beta]-quinoline moiety (rings A, B and C), conjugated pyridone moiety (ring D) and one chiral center at position 20 within the alpha-hydroxy lactone ring with (S) configuration (the E-ring).
External Descriptors Quinoline alkaloids
Estructura 3D
Modelo de Estructura Química Interactiva





Objetivos asociados (humanos)
TOP1 Tclin DNA topoisomerase 1 (0 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
ACHE Tclin Acetylcholinesterase (1 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
PDE5A Tclin Phosphodiesterase 5A (5113 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
EGFR Tclin Epidermal growth factor receptor erbB1 (33727 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CA2 Tclin Carbonic anhydrase II (17698 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ESR1 Tclin Estrogen receptor alpha (17718 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
HMGCR Tclin HMG-CoA reductase (2475 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
NR3C1 Tclin Glucocorticoid receptor (14987 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
INSR Tclin Insulin receptor (5558 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
PGR Tclin Progesterone receptor (8562 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ADRB2 Tclin Beta-2 adrenergic receptor (11824 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CHRM2 Tclin Muscarinic acetylcholine receptor M2 (10671 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ADRB1 Tclin Beta-1 adrenergic receptor (6630 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
HTR1A Tclin Serotonin 1a (5-HT1a) receptor (14969 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ADRA2A Tclin Alpha-2a adrenergic receptor (9450 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
AR Tclin Androgen Receptor (11781 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CHRM1 Tclin Muscarinic acetylcholine receptor M1 (12690 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
TOP1 Tclin DNA topoisomerase I (7553 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ACE Tclin Angiotensin-converting enzyme (1423 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
DRD2 Tclin Dopamine D2 receptor (23596 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
MAOA Tclin Monoamine oxidase A (11911 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CNR1 Tclin Cannabinoid CB1 receptor (20913 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
DRD1 Tclin Dopamine D1 receptor (9720 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
DRD4 Tchem Dopamine D4 receptor (7907 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ACHE Tclin Acetylcholinesterase (18204 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
PTGS1 Tclin Cyclooxygenase-1 (9233 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
SLC6A2 Tclin Norepinephrine transporter (10102 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
HRH2 Tclin Histamine H2 receptor (5428 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ADRA1D Tclin Alpha-1d adrenergic receptor (4171 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
HTR1B Tclin Serotonin 1b (5-HT1b) receptor (2801 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
HTR2A Tclin Serotonin 2a (5-HT2a) receptor (14758 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
HTR2C Tclin Serotonin 2c (5-HT2c) receptor (11471 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ADORA1 Tclin Adenosine A1 receptor (17603 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CALCR Tclin Calcitonin receptor (2215 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
SLC6A4 Tclin Serotonin transporter (12625 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ADRA1A Tclin Alpha-1a adrenergic receptor (8359 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
PTGS2 Tclin Cyclooxygenase-2 (13999 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
HRH1 Tclin Histamine H1 receptor (7573 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ADRA1B Tclin Alpha-1b adrenergic receptor (2912 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
OPRM1 Tclin Mu opioid receptor (19785 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
DRD3 Tclin Dopamine D3 receptor (14368 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
AVPR1A Tclin Vasopressin V1a receptor (5412 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
OPRD1 Tclin Delta opioid receptor (15096 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
OPRK1 Tclin Kappa opioid receptor (16155 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
SLC6A3 Tclin Dopamine transporter (10535 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
KCNH2 Tclin HERG (29587 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
HTR4 Tclin Serotonin 4 (5-HT4) receptor (2068 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ESR2 Tclin Estrogen receptor beta (9272 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CYSLTR1 Tclin Cysteinyl leukotriene receptor 1 (2118 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ERBB2 Tclin Receptor protein-tyrosine kinase erbB-2 (7851 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CHRM4 Tclin Muscarinic acetylcholine receptor M4 (6041 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CHRM5 Tclin Muscarinic acetylcholine receptor M5 (4677 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Objetivos asociados (no humanos)
Agtr2 Angiotensin II type 2 (AT-2) receptor (803 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Mc4r Melanocortin receptor 4 (1205 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Ltc4s Leukotriene C4 synthase (1 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Sigmar1 Sigma opioid receptor (160 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Npy1r Neuropeptide Y receptor type 1 (8 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Cckar Cholecystokinin A receptor (90 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Abcc1 Multidrug resistance-associated protein 1 (42 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Abcb1b P-glycoprotein 1 (174 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Nos2 Nitric oxide synthase, inducible (3573 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Mapk1 MAP kinase ERK2 (650 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Hdac6 Histone deacetylase 6 (222 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Ces1e Liver carboxylesterase 3 (6 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Mmp9 Matrix metalloproteinase 9 (38 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Abcb1a P-glycoprotein 3 (492 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Drosophila melanogaster (359 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Mus musculus (284745 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Rattus norvegicus (775804 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
L1210 (27553 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Colon 26 (524 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
rep Replicase polyprotein 1ab (378 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Txnrd1 Thioredoxin reductase 1, cytoplasmic (45279 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Plasma (328 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Slc22a3 Solute carrier family 22 member 3 (35 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Abcb1a P-glycoprotein 1 and 3 (MDR1a/MDR1b) (23 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Glra2 Glycine receptor (1745 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
SARS-CoV-2 (38078 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Mecanismos de acción
Certificados (CoA, COO, BSE/TSE y tabla de análisis)
C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:

Find and download the COA for your product by matching the lot number on the packaging.

14 results found

Lot NumberCertificate TypeFechaArticulo
G2410411Certificate of AnalysisApr 07, 2026 I127961
G2222423Certificate of AnalysisFeb 04, 2026 I127961
G2222454Certificate of AnalysisFeb 04, 2026 I127961
K2524579Certificate of AnalysisNov 13, 2025 I127961
K2524580Certificate of AnalysisNov 13, 2025 I127961
K2524581Certificate of AnalysisNov 13, 2025 I127961
D2502333Certificate of AnalysisMar 24, 2025 I127961
D2502342Certificate of AnalysisMar 24, 2025 I127961
D2502343Certificate of AnalysisMar 24, 2025 I127961
G2410409Certificate of AnalysisJun 25, 2024 I127961
G2410410Certificate of AnalysisJun 25, 2024 I127961
I2104359Certificate of AnalysisJun 13, 2023 I127961
I2104358Certificate of AnalysisJun 13, 2023 I127961
G2222489Certificate of AnalysisJun 11, 2022 I127961

Show more ⌵

Propiedades químicas y físicas
SolubilidadSoluble in DMSO (10 mg/ml at 25 °C), water (<1 mg/ml at 25 °C), and ethanol (<1 mg/ml at 25 °C).
SensibilidadLight sensitive
Peso molecular586.700 g/mol
XLogP33.000
Hydrogen Bond Donor Count1
Hydrogen Bond Acceptor Count8
Rotatable Bond Count5
Exact Mass586.279 Da
Monoisotopic Mass586.279 Da
Topological Polar Surface Area113.000 Ų
Heavy Atom Count43
Formal Charge0
Complexity1200.000
Isotope Atom Count0
Defined Atom Stereocenter Count1
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
The total count of all stereochemical bonds0
Covalently-Bonded Unit Count1
Preguntas frecuentes y artículos
Citations of This Product
Referencias
1. Yifan Wu, Xiaoxia Gong, Jianzhong Shen, Kui Zhu.  (2023)  Postantibiotic leukocyte enhancement-mediated reduction of intracellular bacteria by macrophages.  Journal of Advanced Research,      [PMID:37290606] [10.1016/j.jare.2023.05.010]
2. Zhongcheng Yang, Zhijun Cao, Wenxin Wang, Ya Chen, Wanqiu Huang, Shixuan Jiao, Siliang Chen, Lianru Chen, Yuxia Liu, Jianming Mao, Luyong Zhang, Zheng Li.  (2023)  Design, synthesis, and biological evaluation studies of novel carboxylesterase 2 inhibitors for the treatment of irinotecan-induced delayed diarrhea.  BIOORGANIC CHEMISTRY,      [PMID:37300962] [10.1016/j.bioorg.2023.106625]
3. Lanhong Su, Wen Pan, Xiangxia Li, Xingyu Zhou, Xiaopeng Ma, Yuanzeng Min.  (2022)  Utilizing chemotherapy-induced tumor RNA nanoparticles to improve cancer chemoimmunotherapy.  Acta Biomaterialia,      [PMID:36563773] [10.1016/j.actbio.2022.12.039]
4. Lanhong Su, Yuhao Hao, Rui Li, Wen Pan, Xiaopeng Ma, Jianping Weng, Yuanzeng Min.  (2022)  Red blood cell-based vaccines for ameliorating cancer chemoimmunotherapy.  Acta Biomaterialia,      [PMID:36241013] [10.1016/j.actbio.2022.10.001]
5. Bo Lv, Ruijie Xu, Xinrui Xing, Chuyao Liao, Zunjian Zhang, Pei Zhang, Fengguo Xu.  (2022)  Discovery of Synergistic Drug Combinations for Colorectal Cancer Driven by Tumor Barcode Derived from Metabolomics “Big Data”.  Metabolites,  12  (6): (494).  [PMID:35736427] [10.3390/metabo12060494]
6. Jiao Yang Lu, Fu Rui Zhang, Xue Zhi Ding, Li Qiu Xia, Wei Tao Huang.  (2021)  Natural interface guiding cell: Directly using waste fish scales with rich micro/nano structures for control of cell behaviors.  APPLIED SURFACE SCIENCE,      [PMID:] [10.1016/j.apsusc.2021.152348]
7. Yue Shi-Jun, Qin Yi-Feng, Kang An, Tao Hui-Juan, Zhou Gui-Sheng, Chen Yan-Yan, Jiang Jian-Qin, Tang Yu-Ping, Duan Jin-Ao.  (2021)  Total Flavonoids of Glycyrrhiza uralensis Alleviates Irinotecan-Induced Colitis via Modification of Gut Microbiota and Fecal Metabolism.  Frontiers in Immunology,      [PMID:34025639] [10.3389/fimmu.2021.628358]
8. Dou-Dou XU, Xiao-Ying HOU, Ou WANG, Di WANG, Dan-Ting LI, Si-Yuan QIN, Bo LV, Xiao-Min DAI, Zun-Jian ZHANG, Jian-Bo WAN, Feng-Guo XU.  (2021)  A four-component combination derived from Huang-Qin Decoction significantly enhances anticancer activity of irinotecan.  Chinese Journal of Natural Medicines,      [PMID:33941341] [10.1016/S1875-5364(21)60034-1]
9. Ling Duan, Leijiao Deng, Dabin Wang, Shoucheng Ma, Chunmei Li, Da Zhao.  (2017)  Treatment mechanism of matrine in combination with irinotecan for colon cancer.  Oncology Letters,  14  (2): (2300-2304).  [PMID:28781667] [10.3892/ol.2017.6407]
10. Zhou Hongyan, Hu Dingxin, Zhao Xian, Qin Siyuan, Nong Qiyao, Tian Yuan, Zhang Zunjian, Dong Haijuan, Zhang Pei, Xu Fengguo.  (2024)  An optimal combination of four active components in Huangqin decoction for the synergistic sensitization of irinotecan against colorectal cancer.  Chinese Medicine,  19  (1): (1-12).  [PMID:38956673] [10.1186/s13020-024-00967-1]
11. Miaomiao Sun, Honghong Zhan, Xiaoliang Long, Ali M. Alsayed, Zhe Wang, Fancheng Meng, Guowei Wang, Jingxin Mao, Zhihua Liao, Min Chen.  (2024)  Dehydrocostus lactone alleviates irinotecan-induced intestinal mucositis by blocking TLR4/MD2 complex formation.  PHYTOMEDICINE,      [PMID:38518649] [10.1016/j.phymed.2024.155371]
12. Ya-Kun Zhang, Jian-Bo Tong, Hong-Yan Zhang, Mu-Xuan Luo, Zhi-Peng Qing, Cheng-Jian Tan.  (2025)  Design, synthesis, and antitumor evaluation of sophoridine derivatives as topoisomerase I inhibitors based on the topomer CoMFA model.  JOURNAL OF MOLECULAR STRUCTURE,      [PMID:] [10.1016/j.molstruc.2025.142005]
13. Yukun Zhong, Haining Li, Teng Jiang, Xueliang Mu, Munetoshi Seki, U Kei Cheang.  (2024)  Double-Layered Metal-Organic-Frameworks-Based Microswimmers for Adaptive Dual-Drug Anti-Cancer Therapy Using Artemisinin-Based Compounds.  Advanced Intelligent Systems,      [PMID:] [10.1002/aisy.202400244]
14. Yuan-yuan Zhai, Qiang Wang, Qi-yao Nong, Mei-yu Gao, Ying Zhang, Qin-wen Xiao, Yuan Tian, Zun-jian Zhang, Feng-guo Xu, Pei Zhang.  (2025)  Pitavastatin overcomes multi-drug resistance in CRC and NSCLC by targeting the NRP1-ZFX axis.  BIOCHEMICAL PHARMACOLOGY,      [PMID:40684995] [10.1016/j.bcp.2025.117183]
15. Lumei Dai, Shifang Wen, Yaling Chen, Xinchun Li, Bing Zhao, Xinyu You, Rongqiang Li, Bin Zhang.  (2025)  Self-assembled dual-target ibuprofen-irinotecan conjugate for colorectal cancer therapy.  BIOORGANIC & MEDICINAL CHEMISTRY,      [PMID:40850193] [10.1016/j.bmc.2025.118367]
16. Yaowei Guo, Jin Liu, Qinglin Tang, Cuicui Li, Yanying Zhang, Yao Wang, Yanxin Wang, Yupeng Bi, Christopher D. Snow, Matt J. Kipper, Laurence A. Belfiore, Jianguo Tang.  (2022)  Lanthanide (Eu3+/Tb3+)-Loaded γ-Cyclodextrin Nano-Aggregates for Smart Sensing of the Anticancer Drug Irinotecan.  INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES,  23  (12): (6597).  [PMID:35743042] [10.3390/ijms23126597]
17. Mengjing Zhao, Tianpeng Zhang, Fangjun Yu, Lianxia Guo, Baojian Wu.  (2018)  E4bp4 regulates carboxylesterase 2 enzymes through repression of the nuclear receptor Rev-erbα in mice.  BIOCHEMICAL PHARMACOLOGY,      [PMID:29653076] [10.1016/j.bcp.2018.04.005]
18. Zhao Xian, Xu Ruijie, Zhai Yuanyuan, Wang Yi, Zhang Yuxin, Tian Yuan, Xu Fengguo, Zhang Pei.  (2025)  Liposomal Vardenafil and Linagliptin Combined with Irinotecan for Synergistic Colorectal Cancer Therapy.  PHARMACEUTICAL RESEARCH,      [PMID:40473893] [10.1007/s11095-025-03876-6]
19. Shuiling Jin, Aifang Zhou, Qi Zhang, Di Zhao, Xintong Dong, Hong-Min Meng, Zhengquan Yu, Zhaohui Li.  (2025)  Engineered Cancer Cell Membrane-Functionalized Metal-Organic Frameworks for Irinotecan/Curcumin Codelivery in Colorectal Cancer: Enhanced Efficacy and Mitigated Toxicity.  International Journal of Nanomedicine,      [PMID:41287765] [10.2147/IJN.S558675]
20. Jiang Huan-guo, Zhan Zhi-kun, Tian Ling-min, Chen Yu-lian, Cai Mei-qun, Ge Guang-bo, Chen Xin, Wei Chuan-liang, Tang Lan.  (2026)  Oridonin exerts dual therapeutic effects in MASLD mice by integrating lipid homeostasis and drug bioactivation via the LXRα–CES1/CES2 pathway.  ACTA PHARMACOLOGICA SINICA,      [PMID:41639319] [10.1038/s41401-025-01737-x]
21. Yunhan Wang, Xinming Zhang, Fang Fang, Yunyan Chen, Yu Sun.  (2026)  NIR-activatable and colorectal cancer-targeted lipid polymer hybrid nanoparticles: Design and in vivo assessment.  JOURNAL OF DISPERSION SCIENCE AND TECHNOLOGY,      [PMID:] [10.1080/01932691.2026.2625044]
22. Yuanyuan Zhang, Mingyang Liu, Yifan Zhang, Fengxia Qin, Yuan Tian, Fengguo Xu, Yuxin Zhang, Pei Zhang.  (2026)  Nigakinone enhances FXR expression to synergize with irinotecan in suppressing colorectal cancer cells and xenografts.  BIOCHEMICAL PHARMACOLOGY,      [PMID:] [10.1016/j.bcp.2026.117904]
23. Nishtha Thakur, Pablo Mota-Santiago, Shuddhodana, Zaher Judeh.  (2026)  Interfacial Modulation of Cochleate Assembly via Cationic Surfactant Enables Enhanced Encapsulation of Water-Soluble Drugs.  COLLOIDS AND SURFACES B-BIOINTERFACES,      [PMID:] [10.1016/j.colsurfb.2026.115601]
24. Mengxi Xiang, Cheng Zhou, Chundong Yao, Jia Liu, Lin Wang, Zheng Wang.  (2026)  A Self-Assembled Irinotecan Nanomedicine Abrogates Steatohepatitis-Induced Liver Metastasis and Potentiates Antitumor Efficacy against Colorectal Cancer.  ACS Nano,      [PMID:] [10.1021/acsnano.6c00855]
Calculadoras de soluciones
Reseñas

Reseñas de cliente

Shall we send you a message when we have discounts available?

Remind me later

Thank you! Please check your email inbox to confirm.

Oops! Notifications are disabled.